Company News
Astellas' PADCEV Gains CDSCO Approval, Doubles Survival
CDSCO approves Astellas' PADCEV (enfortumab vedotin) plus pembrolizumab as first‑line therapy for advanced urothelial cancer in India.
Phase 3 EV‑302 trial showed median overall survival of 31.5 month
